StockWatch
·
Q2 FY-2027 RESULTS · SUDEEPPHRM

Sudeep Q2 FY27: consol PAT +11% YoY to ₹51.8 Cr, EBITDA hits guided 37% band

PAT +10.8% YoY · revenue +20.9% · margins expanding · beat vs street

Q2 FY27 resultsSUDEEPPHRMSudeep Pharma Ltd28 Oct 2026 · 3 min read
Revenue

₹196.7 Cr

+20.9% YoY

PAT (consolidated)

₹51.81 Cr

+10.8% YoY

Net margin

25.56%

-1.5pp YoY

EPS

₹4.59

Sudeep Pharma's consolidated Q2 FY27 print: revenue ₹196.70 Cr (+20.9% YoY, +24.3% QoQ), PAT ₹51.81 Cr (+10.8% YoY, +27.7% QoQ), EPS ₹4.59. Both land above our pre-result preview's working range (revenue ₹165–180 Cr, PAT ₹43–47 Cr), and EBITDA margin of 37.24% sits inside the preview's 35–37% watch band and inside management's own 37–38% guided recovery band from 34.7% — a line management said would recover "within quarters" at the Q1 call and delivered on this quarter. Analyst coverage is thin (2 analysts, 1 Hold/1 Sell, median target ₹663.50 vs CMP ₹966.2) and no public PAT/revenue consensus exists to benchmark against; against our own pre-result range the print is a clear beat on revenue, margin and profit.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹196.7 Cr+24.3%+20.9%
Expenses₹131.65 Cr+20.3%+16.2%
PAT₹51.81 Cr+27.7%+10.8%
Net margin25.56%+0.8pp-1.5pp
EPS₹4.59+27.9%+9.3%

The EBITDA bridge (PBT + D&A + finance costs − other income) rose to ₹73.24 Cr from ₹55.46 Cr a year ago, with the gain concentrated in the Pharmaceutical, food & nutrition segment — external revenue up 57.5% YoY to ₹142.50 Cr, segment profit nearly doubling (+97.6% YoY). That was offset by Speciality ingredients, where external revenue fell 24.9% YoY to ₹54.20 Cr and segment profit dropped 42.1% YoY — directly contradicting the Q1 guidance that this segment would "return to its historical growth trajectory" in Q2 (the +8.7% QoQ uptick doesn't erase the YoY decline). Net profit margin actually slipped to 25.56% from 27.07% a year ago (even as it improved from 24.79% last quarter), because finance costs (+23.3% YoY to ₹2.81 Cr) and depreciation (+41.1% YoY to ₹5.38 Cr) — both tied to the capex buildout (consolidated PPE went from ₹223.99 Cr at 31 March 2026 to ₹400.57 Cr at 30 September 2026) — plus a higher effective tax rate (27.1% vs 21.4% YoY) ate into the EBITDA gain before it reached the bottom line.

₹
797.7948.961,100.231,251.491,402.751,11907-2708-1809-0910-0510-28Q2 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹1,119, down 3.9% over the past month of trading.

₹ Cr
019.3438.6958.0346.78Q2 FY26rev ₹163 Cr47.7Q3 FY26rev ₹172 Cr48.54Q4 FY26rev ₹182 Cr40.59Q1 FY27rev ₹158 Cr51.81Q2 FY27rev ₹197 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 5 quarters on our records; revenue is at a 5-quarter high.

Beyond the headline

What the summary numbers don't show

EPS (basic, consol) ₹4.59 vs ₹4.20 YoY, ₹3.59 QoQ

What management guided (1 FY-2027 call)
EBITDA margins to recover 37-38% from 34.7% within quarters. Greenfield commissioning Q3 FY27; battery materials targeting two binding off-takes calendar 2026; SAM Phase 1 April 2027. Specialty ingredients expected to return historical growth trajectory Q2.

— This quarter: met

Standalone PAT of ₹42.34 Cr grew 42.4% YoY on revenue up 56.4% YoY, far outpacing the consolidated numbers — confirming the group-level growth drag sits entirely in the Speciality ingredients subsidiaries, not the core standalone pharma/nutrition business. Among this quarter's disclosed developments: USFDA approval for the Gujarat plant (Oct 26) is a regulatory positive for the pharma segment but falls just outside the reporting quarter; the MD transition at the US subsidiary (announced Oct 5) is the execution risk the pre-result preview flagged, and this filing carries no further commentary on it. No standalone management press release accompanied this filing to cross-check against company framing. Beyond reaffirming the 37–38% EBITDA band, the greenfield commissioning (Q3 FY27) and SAM Phase 1 (April 2027) targets from the Q1 call, management offered no new quarter-specific guidance in the filing notes.

  • W1

    Speciality ingredients revenue still down 24.9% YoY at ₹54.20 Cr despite +8.7% QoQ — whether it returns to YoY growth in Q3 tests the guidance management already missed once on this specific line

  • W2

    Greenfield facility commissioning targeted for Q3 FY27 — watch its effect on D&A/finance costs, which already outgrew EBITDA this quarter and compressed NPM

  • W3

    Effective tax rate rose to 27.1% from 21.4% YoY — watch whether this normalises or continues to cap NPM even as EBITDA margin holds the 37–38% band

No exceptional items on either basis; arithmetic ties out exactly for both. Consol PAT used here is 'Profit for the period' (₹51.81 Cr, pre-NCI split, NCI ₹0.36 Cr) — matches our DB's PAT convention (confirmed against prior-quarter/year-ago context figures, which tie exactly). Standalone YoY growth (PAT +42.4%, revenue +56.4%) is far stronger than consolidated (PAT +10.8%, revenue +20.9%); the gap traces to the Speciality ingredients segment (subsidiary-heavy) falling 24.9% YoY — a >3pp standalone/consol divergence worth flagging.

Informational and educational content only. Not investment advice.